About this trial
Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.
Eligibility criteria
Qualifiers
Adult patients between 18-75 years of age
Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment
Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;
Good operative candidate
Disqualifiers
Patients unable to participate in the consent process
Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc
Trial design
Treatments tested in this trial
- NIR-II probe (i.e ICG-CK) incubation solution
Treatment groups
Sponsors and collaborators
Yunnan Cancer Hospital
Lead sponsor
Xiang'an Hospital of Xiamen University
Collaborator